To identify blood-based biomarkers of differential abundance in patients with Type 2 diabetes (T2D) with and without co-morbidities of cardiovascular disease (CVD), stroke and dementia and develop biomarker-based algorithms for the early-stage comorbidity diagnosis.
Identification of biomarkers for diabetes-associated cardiovascular disease. Study of a cohort with detailed clinical phenotyping and cardiovascular disease.
Identification of biomarkers for diabetes-associated stroke. Study of the diabetes and stroke (DAS) cohort - well-characterized patients with stroke, using detailed phenotyping of stroke type and brain imaging of small vessel disease.
Identification of biomarkers for diabetes-associated dementia. Study of Diabetes and Dementia (DAD) cohort - a longitudinal study of patients with mild cognitive impairment and dementia, with an assessment of cognitive function and brain imaging.
Biomarkers identified from phase 1 will be validated in newly recruited patients from the CVD, DAS, and DAD cohorts, with biomarker combination by artificial intelligence machine learning algorithm training and testing.